How to buy Harrow Health stock | $9.89

Harrow Health Inc is a drug manufacturers-specialty & generic business based in the US. Harrow Health shares (HROW) are listed on the NASDAQ and all prices are listed in US Dollars. Harrow Health employs 125 staff and has a trailing 12-month revenue of around 0.00.

Harrow Health stock price (NASDAQ: HROW)

Use our graph to track the performance of HROW stocks over time.

Harrow Health shares at a glance

• Key figures

Information last updated 2021-10-16.

Latest market close	$9.89
52-week range	$4.65 - $11.24
50-day moving average	$9.72
200-day moving average	$8.82
Wall St. target price	$15.31
PE ratio	36.7658
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.27

Buy Harrow Health shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Harrow Health stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Harrow Health price performance over time

Historical closes compared with the close of $9.89 from 2021-10-15

1 week (2021-10-08)	2.49%
1 month (2021-09-17)	4.21%
3 months (2021-07-16)	41.49%
6 months (2021-04-16)	23.63%

1 year (2020-10-16)	69.35%
2 years (2019-10-17)	88.38%
3 years (2018-10-17)	195.22%
5 years (2016-10-17)	204.31%

Is Harrow Health under- or over-valued?

Valuing Harrow Health stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Harrow Health's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Harrow Health's P/E ratio

Harrow Health's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 37x. In other words, Harrow Health shares trade at around 37x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Harrow Health's EBITDA

Harrow Health's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $13.3 million.

The EBITDA is a measure of a Harrow Health's overall financial performance and is widely used to measure a its profitability.

Harrow Health financials

Revenue TTM	$62.6 million
Operating margin TTM	18.07%
Gross profit TTM	$34.4 million
Return on assets TTM	9.04%
Return on equity TTM	39.24%
Profit margin	12.03%
Book value	$0.86
Market capitalisation	$266 million

TTM: trailing 12 months

Shorting Harrow Health shares

There are currently 980,205 Harrow Health shares held short by investors – that's known as Harrow Health's "short interest". This figure is 1.6% down from 995,919 last month.

There are a few different ways that this level of interest in shorting Harrow Health shares can be evaluated.

Harrow Health's "short interest ratio" (SIR)

Harrow Health's "short interest ratio" (SIR) is the quantity of Harrow Health shares currently shorted divided by the average quantity of Harrow Health shares traded daily (recently around 125990.35989717). Harrow Health's SIR currently stands at 7.78. In other words for every 100,000 Harrow Health shares traded daily on the market, roughly 7780 shares are currently held short.

However Harrow Health's short interest can also be evaluated against the total number of Harrow Health shares, or, against the total number of tradable Harrow Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Harrow Health's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Harrow Health shares in existence, roughly 40 shares are currently held short) or 0.0502% of the tradable shares (for every 100,000 tradable Harrow Health shares, roughly 50 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Harrow Health.

Find out more about how you can short Harrow Health stock.

Harrow Health share dividends

We're not expecting Harrow Health to pay a dividend over the next 12 months.

Have Harrow Health's shares ever split?

Harrow Health's shares were split on a 1:5 basis on 7 February 2013. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Harrow Health shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Harrow Health shares which in turn could have impacted Harrow Health's share price.

Harrow Health share price volatility

Over the last 12 months, Harrow Health's shares have ranged in value from as little as $4.65 up to $11.24. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Harrow Health's is 0.9757. This would suggest that Harrow Health's shares are less volatile than average (for this exchange).

Harrow Health overview

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc. , a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc. , a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.

Frequently asked questions

What percentage of Harrow Health is owned by insiders or institutions?
Currently 11.067% of Harrow Health shares are held by insiders and 51.653% by institutions. How many people work for Harrow Health?
Latest data suggests 125 work at Harrow Health. When does the fiscal year end for Harrow Health?
Harrow Health's fiscal year ends in December. Where is Harrow Health based?
Harrow Health's address is: 102 Woodmont Boulevard, Nashville, TN, United States, 37205 What is Harrow Health's ISIN number?
Harrow Health's international securities identification number is: US4158581094 What is Harrow Health's CUSIP number?
Harrow Health's Committee on Uniform Securities Identification Procedures number is: 415858109